Lilly Back In The BACE Space Following Deal With AstraZeneca
This article was originally published in The Pink Sheet Daily
Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.
You may also be interested in...
AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
All clear from monitoring board means firms will roll into the Phase III portion of the AMARANTH trial.
Lilly Poised To Lead In Alzheimer’s, But Success Depends On Solanezumab
Lilly's comprehensive R&D initiative to lead in Alzheimer’s disease includes seven drugs in or nearing the clinic, with an eye on combinations. But until data from a third Phase III trial testing solanezumab read out in late 2016/early 2017, investors remain skeptical.
AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture
The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.